Drug conjugates consisting
of an antineoplastic drug and a targeting
receptor ligand could be effective to overcome the heavy side effects
of unselective anticancer agents. To address this need, we report
here the results of a project aimed to study agonist and antagonist
integrin ligands as targeting head of molecular cargoes for the selective
delivery of 5-fluorouracil (5-FU) to cancer or noncancer cells. Initially,
two fluorescent β-lactam-based integrin ligands were synthesized
and tested for an effective and selective internalization mediated
by α4β1 or α5β1 integrins in Jurkat and K562 cells, respectively. No cellular
uptake was observed for both fluorescent compounds in HEK293 noncancerous
control cells. Afterward, three conjugates composed of the β-lactam-based
integrin ligand, suitable linkers, and 5-FU were realized. The best
compound E, acting as α5β1 integrin
agonist, is able to selectively deliver 5-FU into tumor cells, successfully
leading to cancer cell death.